| NCT03949283 | III | Platinum resistant ovarian cancer | Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | CA, FL, IN, LA, OH, OK, PA, WV | View Drugs | |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04729387 | III | Platinum resistant or refractory gBRCA WT high grade serous or endometrioid ovarian cancer | EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer | AZ, AR, FL, IL, MD, MA, NY, OH, SD, TN, TX | View Drugs | View Results |
Alpelisib | PI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, Piqray | PI3K alpha inhibitor | Approved in Other Cancers | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04209855 | III | Platinum resistant FRalpha+ high grade serous ovarian cancer | MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | AL, AK, AZ, CA, CO, CT, FL, GA, HI, IL, IN, KS, KY, LA, MD, MA, MI, MN, MO, MT, NV, NJ, NY, NC, OH, OK, OR, PA, RI, TN, TX, VA, WA, WV | View Drugs | View Results |
Mirvetuximab soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) | Clinical Trials |
|
|
| NCT05043402 | III | Platinum resistant ovarian cancer that must have had prior bevacizumab | An Open Label Randomized Study of Navicixizumab Plus Paclitaxel and Navicixizumab Monotherapy in Comparison to Paclitaxel Monotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Contact research study staff | View Drugs | View Results |
Navicixizumab | OMP-305B83, anti-DLL4/VEGF bispecific monoclonal antibody OMP-305B83 | DLL4 and VEGF antagonist | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04729608 | III | Platinum resistant high grade serous ovarian cancer; no prior paclitaxel for platinum resistant disease | A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC) | AL, CA, CO, CT, FL, GA, IL, IN, KY, LA, ME, MD, MA, MI, MN, MO, MT, NV, NJ, NM, NY, NC, OH, OK, OR, PA, RI, SC, SD, TN, TX, VA, WA, WV, WI | View Drugs | View Results |
Batiraxcept | anti-AXL fusion protein AVB-S6-500, AVB-S6-500, AVB-500 | GAS6 antagonist | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05116189 | III | Platinum resistant ovarian cancer; 1-2 prior systemic therapies | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65) | CA, FL, GA, IN, MD, MA, NJ, NC, OH, OR, PA, TN, TX, VA | View Drugs | View Results |
Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05281471 | III | Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab | A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer | FL | View Drugs | View Results |
Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Olvimulogene nanivacirepvec | light-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68, GL-ONC1 | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT05257408 | III | Platinum resistant high grade serous or high grade endometrioid ovarian cancer | A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Investigator's Choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | Contact research study staff | View Drugs | View Results |
nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Relacorilant | RELA, CORT125134 | GR antagonist | Clinical Trials |
|
|
| NCT05092360 | III | Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab (≤5 prior therapies for platinum resistant disease) | A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | FL, NY | View Drugs | View Results |
Nemvaleukin alfa | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 | IL-2/IL-15R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04172597 | II | Advanced solid tumors with EGFR or ERBB2 activating mutations | A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | CA | View Drugs | View Results |
Poziotinib | NOV120101, pan-HER kinase inhibitor HM781-36B | EGFR, HER2, HER4 kinase inhibitor | |
|
|
| NCT02843165 | II | Advanced solid tumors with lesion treatable with radiation therapy | Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease | CA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT02364713 | II | Platinum resistant, refractory or persistent ovarian cancer (no measurable disease outside the peritoneal cavity) | MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer | AZ, FL, MN | View Drugs | View Results |
MV-NIS | oncolytic measles virus encoding thyroidal sodium iodide symporter | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT03907475 | II | Advanced solid tumors (with tumor amenable to skin biopsy) | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors | MD | View Drugs | View Results |
Capecitabine | Xeloda, CAPE | RNA processing and thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02834013 | II | Advanced ovarian small cell cancer | DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors | AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04482309 | II | Advanced HER2+ solid tumors | A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) | CA, IL, IN, MA, NJ, NY, NC, TN, TX, VA, WA | View Drugs | |
Trastuzumab deruxtecan | T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a | ADC: anti-HER2 + topoisomerase I inhibitor (Dxd) | Approved in Other Cancers |
|
|
| NCT03732950 | II | Recurrent ovarian cancer | A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling | CA, MN | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03113487 | II | Platinum resistant or refractory ovarian cancer | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | CA | View Drugs | View Results |
p53MVA | Modified Vaccinia Virus Ankara Vaccine Expressing p53, MVAp53 | Immune response against p53 tumor antigen | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03911557 | II | Advanced solid tumors with moderate/high TMB | Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | KY | View Drugs | View Results |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT04056910 | II | Advanced solid tumors with IDH1 mutations | Phase II Study of IDH1 Inhibitor Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Advanced Solid Tumors | PA | View Drugs | |
Ivosidenib | AG-120 | IDH1 inhibitor | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03935893 | II | Advanced solid tumors | A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers | PA | View Drugs | View Results |
Aldesleukin | | IL-2 receptor agonist | Approved in Other Cancers | Autologous TILs | | Immune response against tumor-associated antigens | Clinical Trials | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers |
|
|
| NCT02568267 | II | Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | TX | View Drugs | View Results |
Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers |
|
|
| NCT01851369 | II | Granulosa cell ovarian cancer | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas | MD | View Drugs | View Results |
Methoxyamine | TRC102 | Base excision repair inhibitor | Clinical Trials | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent | Approved in Other Cancers |
|
|
| NCT04171219 | II | Advanced solid tumors | A Phase 2 Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid Cancers | TX | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Talabostat | BXCL701, Val-boro-Pro, talabostat mesylate, PT100 | Dipeptidyl peptidase inhibitor | Clinical Trials |
|
|
| NCT04753216 | II | Platinum resistant or refractory ovarian cancer | A Phase II Trial of Irinotecan Liposome and Bevacizumab in Women With Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | IL | View Drugs | View Results |
Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | Liposomal irinotecan | Onivyde, MM-398, liposome-encapsulated irinotecan hydrochloride PEP02, nal-IRI, nanoliposomal irinotecan | Topoisomerase I inhibitor | |
|
|
| NCT04739618 | II | Advanced solid tumors - intratumoral injection | A Phase 2 Trial of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy in Patients With Metastatic Solid Cancer | AZ | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Thermotherapy | | | Clinical Trials |
|
|
| NCT04639219 | II | Advanced solid tumors with ERBB2 MUT | A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology | CA, IL, IN, MA, NJ, NY, TX, VA | View Drugs | |
Trastuzumab deruxtecan | T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a | ADC: anti-HER2 + topoisomerase I inhibitor (Dxd) | Approved in Other Cancers |
|
|
| NCT02312245 | II | Recurrent ovarian cancer | Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers | AZ, FL, MN | View Drugs | |
Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03693014 | II | Advanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatment | A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade | CT, NJ, NY, PA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT04770246 | II | Advanced solid tumors | A Phase 2 Study of TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations | CA, NY, OH, PA, TX | View Drugs | View Results |
TAS-117 | | Akt inhibitor | Clinical Trials |
|
|
| NCT04771520 | II | Advanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I) | Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors | TX | View Drugs | |
Avapritinib | | PDGFRa and c-Kit inhibitor | Approved in Other Cancers |
|
|
| NCT04233567 | II | Advanced solid tumors with FGFR alterations | A Phase II Study of Oral Infigratinib in Adult Patients With Advanced or Metastatic Solid Tumors With FGFR1-3 Gene Fusions or Other FGFR Genetic Alterations | OH | View Drugs | View Results |
Infigratinib | BGJ398, pan FGFR Kinase Inhibitor BGJ398 | pan-FGFR kinase inhibitor | Approved in Other Cancers |
|
|
| NCT04876456 | II | Recurrent Germ Cell Tumors | A Phase II Trial Evaluating the Efficacy of Cabozantinib in the Treatment of Incurable Patients With Refractory Germ Cell Tumors | IN | View Drugs | |
|